Treatment of Uterine Fibroids With the Selective Progesterone Receptor Modulator CDB-2914

February 14, 2022 updated by: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Evaluation of Whether the Selective Progesterone Receptor Modulator CDB-2914 Can Shrink Leiomyomata

This study will evaluate whether the experimental drug ulipristal acetate can shrink uterine fibroids in pre-menopausal women.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Uterine leiomyomata (fibroids) are a common benign tumor of the uterine muscle in pre-menopausal women that may cause bleeding, pelvic pain and pressure. Because fibroids grow in the presence of estrogen, medical therapies that decrease estrogen levels (like Gonadotropin releasing hormone,GnRH analog) cause fibroids to shrink and so may relieve symptoms. However, such medication can only be given short-term and has inconvenient side effects such as hot-flashes. Thus, many women with symptomatic fibroids choose to have them removed surgically, either individually or by removing the uterus via hysterectomy.

Women between 25 and 50 years of age who have regular menstrual cycles and a history of uterine fibroids that cause heavy bleeding, pressure, or pain may be eligible for this study. Candidates are screened with a medical history and physical examination, including breast and pelvic examination, blood and urine tests, a quality-of-life questionnaire, and a home urine test for leuteinizing hormone (LH) surge. They are given a diary to record the LH surge, days of vaginal spotting or bleeding, and symptoms. Participation includes the following:

Baseline Studies (First Menstrual Cycle)

  • Magnetic resonance imaging (MRI): The subject lies in the MRI scanner, a narrow cylinder with a strong magnetic field, for imaging the uterus.
  • Saline hysterosonogram: This is an ultrasound examination of the uterus. A speculum is placed in the vagina and a small amount of liquid is inserted into the uterus. A probe is then inserted into the vagina. The probe emits and receives sound waves that are used to visualize the fibroids and surrounding structures.

Study Drug Phase (Second through Fourth Menstrual Cycles)

  • Subjects are randomly assigned to take ulipristal acetate or placebo (inactive compound) once a day by mouth on an empty stomach for three menstrual cycles or up to 102 days if menstrual cycles are irregular or stop.
  • Pregnancy test on first or second day of every menstrual cycle.
  • Blood tests every 2 weeks to measure effects of study medication on hormones, blood count, blood chemistries and liver function.
  • 24-hour urine collections three times during the study, about once a month, to measure cortisol and check adrenal gland function.
  • Repeat transvaginal ultrasound after 4-6 weeks of study drug to check fibroid growth.
  • Repeat hysterosonogram and MRI within 2 weeks of surgery to count and measure the fibroids. or placebo (inactive compound) once a day by mouth on an empty stomach for three menstrual cycles or up to 102 days if menstrual cycles are irregular or stop.
  • Pregnancy test on first or second day of every menstrual cycle.
  • Blood tests every 2 weeks to measure effects of study medication on hormones, blood count, blood chemistries and liver function.
  • 24-hour urine collections three times during the study, about once a month, to measure cortisol and check adrenal gland function.
  • Repeat transvaginal ultrasound after 4-6 weeks of study drug to check fibroid growth.
  • Repeat hysterosonogram and MRI within 2 weeks of surgery to count and measure the fibroids. or placebo (inactive compound) once a day by mouth on an empty stomach for three menstrual cycles or up to 102 days if menstrual cycles are irregular or stop.
  • Pregnancy test on first or second day of every menstrual cycle.
  • Blood tests every 2 weeks to measure effects of study medication on hormones, blood count, blood chemistries and liver function.
  • 24-hour urine collections three times during the study, about once a month, to measure cortisol and check adrenal gland function.
  • Repeat transvaginal ultrasound after 4-6 weeks of study drug to check fibroid growth.
  • Repeat hysterosonogram and MRI within 2 weeks of surgery to count and measure the fibroids.

Study Type

Interventional

Enrollment (Actual)

72

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Maryland
      • Bethesda, Maryland, United States, 20892
        • National Institutes of Health Clinical Center, 9000 Rockville Pike
      • Bethesda, Maryland, United States, 20891
        • NIH Clinical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

25 years to 50 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

INCLUSION CRITERIA:

  • Female gender-to evaluate effects in the target population for clinical trials.
  • History of uterine leiomyoma causing symptoms of bleeding, pressure, or pain, as defined by the American College of Obstetrics and Gynecology (ACOG) practice bulletin:
  • Excessive uterine bleeding will be evidenced by either of the following-profuse bleeding with flooding or clots or repetitive periods lasting for more than 8 days; or anemia due to acute or chronic blood loss;

OR

  • Pelvic discomfort caused by leiomyomata, either acute and severe or chronic lower abdominal or low back pressure or bladder pressure with urinary frequency not due to urinary tract infection.
  • Uterine leiomyoma(ta) of at least 2 cm size.
  • In good health. Chronic medication use is acceptable except for glucocorticoid use. Other chronic medication use may be acceptable at the discretion of the research team. Interval use of over-the-counter drugs is acceptable but must be recorded.
  • Menstrual cycles of 24 - 35 days.
  • Hemoglobin greater than 10 g/dL (for those wishing surgery); iron may be administered to improve red blood cell counts.
  • Willing and able to comply with study requirements.
  • Age 25 to 50.
  • Using mechanical (condoms, diaphragms) sterilization or abstinence methods of contraception for the duration of the study.
  • Negative urine pregnancy test.
  • Body mass index (BMI) less than or equal to 33, if a surgical candidate or less than or equal to 35, if not a surgical candidate.
  • Creatinine less than 1.3 mg/dL.
  • Liver function tests within 130% of upper limit.
  • If interested in hysterectomy, no desire for fertility.

EXCLUSION CRITERIA:

  • Significant abnormalities in the history, physical or laboratory examination.
  • Pregnancy.
  • Lactation.
  • Use of oral, injectable or inhaled glucocorticoids or megestrol within the last year.
  • Unexplained vaginal bleeding.
  • History of malignancy within the past 5 years.
  • Use of estrogen or progesterone-containing compounds, such as oral contraceptives and hormone replacement therapy, within 8 weeks of study entry, including transdermal, injectable, vaginal and oral preparations.
  • Use of agents known to induce hepatic P450 enzymes; use of imidazoles.
  • Current use of Gonadotropin-releasing hormone (GnRH) analogs or other compounds that affect menstrual cyclicity.
  • Follicle stimulating hormone (FSH) greater than 20 IU/mL.
  • Untreated cervical dysplasia.
  • Need for interval use of narcotics.
  • Abnormal adnexal/ovarian mass.
  • Use of herbal medication having estrogenic or antiestrogenic effects within the past 3 months.
  • Contradiction to anesthesia, for women planning surgery.
  • Genetic causes of leiomyomata.
  • Previous participation in the study.
  • Known recent rapid growth of fibroids, defined as a doubling in size in six months.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: ulipristal acetate -20 mg
20 mg daily dose ulipristal acetate for three menstrual cycles or up to 102 days
Drug: ulipristal acetate 20 mg
ulipristal acetate at a daily dose of 20 mg, given once daily for three menstrual cycles or 90 - 102 days if amenorrheic
Other Names:
  • VA2914; CDB-2914
Active Comparator: ulipristal acetate - 10 mg
10 mg daily dose ulipristal acetate for three menstrual cycles or up to 102 days
Drug: ulipristal acetate 10 mg
10 mg given daily for three menstrual cycles or 90 - 102 days
Other Names:
  • VA2914; CDB2914
Placebo Comparator: Placebo
Placebo taken daily for three menstrual cycles or up to 102 days
Drug: placebo
placebo given once daily for 3 menstrual cycles or 90 - 102 days
No Intervention: Pre-ulipristal acetate 10 mg
Subjects were studied during one baseline cycle without any intervention before entering ulipristal acetate 10 mg arm
No Intervention: Pre-ulipristal acetate 20 mg
Subjects were studied during one baseline cycle without any intervention before entering ulipristal acetate 20 mg arm
No Intervention: Pre-placebo
Subjects were studied during one baseline cycle without any intervention before entering placebo arm

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Shrinkage of Fibroids - Size of Fibroids
Time Frame: 3 months (baseline to end of treatment)
The primary outcome, fibroid volume, was calculated by an ellipsoid formula (π/6xd1xd2xd3) using orthogonal three-dimensional measurements taken from pelvic MRI scan. Individual volumes were summed to assess total fibroid volume for each woman, which were log-transformed before analysis. Women with paired MRI results were included in this intent to treat analysis, even if they did not take all study medication. Fibroids were included if they were seen on both studies.The absolute change in cm3 between baseline and end of treatment was calculated and its log was used for statistics and reporting the results in the data table below.
3 months (baseline to end of treatment)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Short Form-36 and Uterine Fibroid Symptom Quality of Life
Time Frame: 3 months (Baseline to end of treatment 1)
The short form-36 (SF-36)and Uterine Fibroid Symptom Quality of Life (UFS-QOL) questionnaires were given before and at treatment end with scales of 0 - 100. SF-36 scales = mental and physical well-being. The UFS subscales are symptom severity, concern, activities, energy and mood, control, self-consciousness, sexual functioning compiled into an overall QOL score. Higher results indicate better QOL on all but symptom severity (higher = worse). The change in scores from baseline to end of treatment was calculated.
3 months (Baseline to end of treatment 1)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Collaborators

HRA Pharma

Investigators

  • Principal Investigator: Lynnette K Nieman, MD, NICHD, NIH

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

February 1, 2006

Primary Completion (Actual)

July 1, 2009

Study Completion (Actual)

August 1, 2010

Study Registration Dates

First Submitted

February 10, 2006

First Submitted That Met QC Criteria

February 9, 2006

First Posted (Estimate)

February 10, 2006

Study Record Updates

Last Update Posted (Actual)

March 8, 2022

Last Update Submitted That Met QC Criteria

February 14, 2022

Last Verified

November 1, 2012

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 060090
  • 1ZIAHD000637-17 (U.S. NIH Grant/Contract)
  • 06-CH-0090 (Other Identifier: NIH IRB)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Leiomyoma

Clinical Trials on ulipristal acetate 20 mg

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Korea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe